Clinical Trial Update: TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

View source ↗

Summary

This completed clinical trial update describes real-world treatment patterns and clinical outcomes for patients with HR+/HER2- advanced/metastatic breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• FEMARA (letrozole)
• Faslodex (fulvestrant)
• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer | Status: COMPLETED